Molecular-targeted therapy is a novel strategy born from our increasing understanding of the underlying pathways and key molecules involved in tumor growth and progression. Theoretically, the specificity of molecular targeted therapy should improve the therapeutic window by affecting the tumor cells and sparing normal cell.
Highlights
The global Molecular Targeted Therapy market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
North American market for Molecular Targeted Therapy is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
Asia-Pacific market for Molecular Targeted Therapy is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The global market for Molecular Targeted Therapy in Lung Cancer is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The major global companies of Molecular Targeted Therapy include Phoenix Molecular Designs, Prelude Therapeutics, Tempus, Bracco, iOmx Therapeutics, OncoDNA, Sapience Therapeutics, Caris Life Sciences and Hera Biolabs, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
Considering the economic change due to COVID-19, Monoclonal Antibodies, which accounted for % of the global market of Molecular Targeted Therapy in 2021, is expected to reach US$ million by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Molecular Targeted Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Molecular Targeted Therapy.
The Molecular Targeted Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Molecular Targeted Therapy market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Molecular Targeted Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Phoenix Molecular Designs
Prelude Therapeutics
Tempus
Bracco
iOmx Therapeutics
OncoDNA
Sapience Therapeutics
Caris Life Sciences
Hera Biolabs
CV6 Therapeutics
Carrick Therapeutics
Foundation Medicine
Cybrexa Therapeutics
Product Type Insights
Global markets are presented by Molecular Targeted Therapy type, along with growth forecasts through 2028. Estimates on revenue are based on the price in the supply chain at which the Molecular Targeted Therapy are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
Molecular Targeted Therapy segment by Type
Monoclonal Antibodies
Small Molecule Inhibitors
Application Insights
This report has provided the market size (revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Molecular Targeted Therapy market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Molecular Targeted Therapy market.
Molecular Targeted Therapy Segment by Application
Lung Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Others
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Molecular Targeted Therapy market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Molecular Targeted Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Molecular Targeted Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Molecular Targeted Therapy industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Molecular Targeted Therapy.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Molecular Targeted Therapy companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Molecular Targeted Therapy Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Monoclonal Antibodies
1.2.3 Small Molecule Inhibitors
1.3 Market by Application
1.3.1 Global Molecular Targeted Therapy Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Leukemia
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Molecular Targeted Therapy Market Perspective (2017-2028)
2.2 Molecular Targeted Therapy Growth Trends by Region
2.2.1 Molecular Targeted Therapy Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Molecular Targeted Therapy Historic Market Size by Region (2017-2022)
2.2.3 Molecular Targeted Therapy Forecasted Market Size by Region (2023-2028)
2.3 Molecular Targeted Therapy Market Dynamics
2.3.1 Molecular Targeted Therapy Industry Trends
2.3.2 Molecular Targeted Therapy Market Drivers
2.3.3 Molecular Targeted Therapy Market Challenges
2.3.4 Molecular Targeted Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Molecular Targeted Therapy Players by Revenue
3.1.1 Global Top Molecular Targeted Therapy Players by Revenue (2017-2022)
3.1.2 Global Molecular Targeted Therapy Revenue Market Share by Players (2017-2022)
3.2 Global Molecular Targeted Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Molecular Targeted Therapy Revenue
3.4 Global Molecular Targeted Therapy Market Concentration Ratio
3.4.1 Global Molecular Targeted Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Molecular Targeted Therapy Revenue in 2021
3.5 Molecular Targeted Therapy Key Players Head office and Area Served
3.6 Key Players Molecular Targeted Therapy Product Solution and Service
3.7 Date of Enter into Molecular Targeted Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Molecular Targeted Therapy Breakdown Data by Type
4.1 Global Molecular Targeted Therapy Historic Market Size by Type (2017-2022)
4.2 Global Molecular Targeted Therapy Forecasted Market Size by Type (2023-2028)
5 Molecular Targeted Therapy Breakdown Data by Application
5.1 Global Molecular Targeted Therapy Historic Market Size by Application (2017-2022)
5.2 Global Molecular Targeted Therapy Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Molecular Targeted Therapy Market Size (2017-2028)
6.2 North America Molecular Targeted Therapy Market Size by Country (2017-2022)
6.3 North America Molecular Targeted Therapy Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Molecular Targeted Therapy Market Size (2017-2028)
7.2 Europe Molecular Targeted Therapy Market Size by Country (2017-2022)
7.3 Europe Molecular Targeted Therapy Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Molecular Targeted Therapy Market Size (2017-2028)
8.2 Asia-Pacific Molecular Targeted Therapy Market Size by Country (2017-2022)
8.3 Asia-Pacific Molecular Targeted Therapy Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Molecular Targeted Therapy Market Size (2017-2028)
9.2 Latin America Molecular Targeted Therapy Market Size by Country (2017-2022)
9.3 Latin America Molecular Targeted Therapy Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Molecular Targeted Therapy Market Size (2017-2028)
10.2 Middle East & Africa Molecular Targeted Therapy Market Size by Country (2017-2022)
10.3 Middle East & Africa Molecular Targeted Therapy Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Phoenix Molecular Designs
11.1.1 Phoenix Molecular Designs Company Detail
11.1.2 Phoenix Molecular Designs Business Overview
11.1.3 Phoenix Molecular Designs Molecular Targeted Therapy Introduction
11.1.4 Phoenix Molecular Designs Revenue in Molecular Targeted Therapy Business (2017-2022)
11.1.5 Phoenix Molecular Designs Recent Development
11.2 Prelude Therapeutics
11.2.1 Prelude Therapeutics Company Detail
11.2.2 Prelude Therapeutics Business Overview
11.2.3 Prelude Therapeutics Molecular Targeted Therapy Introduction
11.2.4 Prelude Therapeutics Revenue in Molecular Targeted Therapy Business (2017-2022)
11.2.5 Prelude Therapeutics Recent Development
11.3 Tempus
11.3.1 Tempus Company Detail
11.3.2 Tempus Business Overview
11.3.3 Tempus Molecular Targeted Therapy Introduction
11.3.4 Tempus Revenue in Molecular Targeted Therapy Business (2017-2022)
11.3.5 Tempus Recent Development
11.4 Bracco
11.4.1 Bracco Company Detail
11.4.2 Bracco Business Overview
11.4.3 Bracco Molecular Targeted Therapy Introduction
11.4.4 Bracco Revenue in Molecular Targeted Therapy Business (2017-2022)
11.4.5 Bracco Recent Development
11.5 iOmx Therapeutics
11.5.1 iOmx Therapeutics Company Detail
11.5.2 iOmx Therapeutics Business Overview
11.5.3 iOmx Therapeutics Molecular Targeted Therapy Introduction
11.5.4 iOmx Therapeutics Revenue in Molecular Targeted Therapy Business (2017-2022)
11.5.5 iOmx Therapeutics Recent Development
11.6 OncoDNA
11.6.1 OncoDNA Company Detail
11.6.2 OncoDNA Business Overview
11.6.3 OncoDNA Molecular Targeted Therapy Introduction
11.6.4 OncoDNA Revenue in Molecular Targeted Therapy Business (2017-2022)
11.6.5 OncoDNA Recent Development
11.7 Sapience Therapeutics
11.7.1 Sapience Therapeutics Company Detail
11.7.2 Sapience Therapeutics Business Overview
11.7.3 Sapience Therapeutics Molecular Targeted Therapy Introduction
11.7.4 Sapience Therapeutics Revenue in Molecular Targeted Therapy Business (2017-2022)
11.7.5 Sapience Therapeutics Recent Development
11.8 Caris Life Sciences
11.8.1 Caris Life Sciences Company Detail
11.8.2 Caris Life Sciences Business Overview
11.8.3 Caris Life Sciences Molecular Targeted Therapy Introduction
11.8.4 Caris Life Sciences Revenue in Molecular Targeted Therapy Business (2017-2022)
11.8.5 Caris Life Sciences Recent Development
11.9 Hera Biolabs
11.9.1 Hera Biolabs Company Detail
11.9.2 Hera Biolabs Business Overview
11.9.3 Hera Biolabs Molecular Targeted Therapy Introduction
11.9.4 Hera Biolabs Revenue in Molecular Targeted Therapy Business (2017-2022)
11.9.5 Hera Biolabs Recent Development
11.10 CV6 Therapeutics
11.10.1 CV6 Therapeutics Company Detail
11.10.2 CV6 Therapeutics Business Overview
11.10.3 CV6 Therapeutics Molecular Targeted Therapy Introduction
11.10.4 CV6 Therapeutics Revenue in Molecular Targeted Therapy Business (2017-2022)
11.10.5 CV6 Therapeutics Recent Development
11.11 Carrick Therapeutics
11.11.1 Carrick Therapeutics Company Detail
11.11.2 Carrick Therapeutics Business Overview
11.11.3 Carrick Therapeutics Molecular Targeted Therapy Introduction
11.11.4 Carrick Therapeutics Revenue in Molecular Targeted Therapy Business (2017-2022)
11.11.5 Carrick Therapeutics Recent Development
11.12 Foundation Medicine
11.12.1 Foundation Medicine Company Detail
11.12.2 Foundation Medicine Business Overview
11.12.3 Foundation Medicine Molecular Targeted Therapy Introduction
11.12.4 Foundation Medicine Revenue in Molecular Targeted Therapy Business (2017-2022)
11.12.5 Foundation Medicine Recent Development
11.13 Cybrexa Therapeutics
11.13.1 Cybrexa Therapeutics Company Detail
11.13.2 Cybrexa Therapeutics Business Overview
11.13.3 Cybrexa Therapeutics Molecular Targeted Therapy Introduction
11.13.4 Cybrexa Therapeutics Revenue in Molecular Targeted Therapy Business (2017-2022)
11.13.5 Cybrexa Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Phoenix Molecular Designs
Prelude Therapeutics
Tempus
Bracco
iOmx Therapeutics
OncoDNA
Sapience Therapeutics
Caris Life Sciences
Hera Biolabs
CV6 Therapeutics
Carrick Therapeutics
Foundation Medicine
Cybrexa Therapeutics
听
听
*If Applicable.
